Skip to main content
SpringerLink
Log in

The Role of Epigenomics in the Study of Cancer Biomarkers and in the Development of Diagnostic Tools

  • Chapter
Book cover Advances in Cancer Biomarkers

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 867))

Abstract

Epigenetics plays a key role in cancer development. Genetics alone cannot explain sporadic cancer and cancer development in individuals with no family history or a weak family history of cancer. Epigenetics provides a mechanism to explain the development of cancer in such situations. Alterations in epigenetic profiling may provide important insights into the etiology and natural history of cancer. Because several epigenetic changes occur before histopathological changes, they can serve as biomarkers for cancer diagnosis and risk assessment. Many cancers may remain asymptomatic until relatively late stages; in managing the disease, efforts should be focused on early detection, accurate prediction of disease progression, and frequent monitoring. This chapter describes epigenetic biomarkers as they are expressed during cancer development and their potential use in cancer diagnosis and prognosis. Based on epigenomic information, biomarkers have been identified that may serve as diagnostic tools; some such biomarkers also may be useful in identifying individuals who will respond to therapy and survive longer. The importance of analytical and clinical validation of biomarkers is discussed, along with challenges and opportunities in this field.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jones PA (2005) Overview of cancer epigenetics. Semin Hematol 42:S3–S8

    Article  CAS  PubMed  Google Scholar 

  2. Khare S, Verma M (2012) Epigenetics of colon cancer. Methods Mol Biol 863:177–185

    Article  CAS  PubMed  Google Scholar 

  3. Mishra A, Verma M (2012) Epigenetics of solid cancer stem cells. Methods Mol Biol 863:15–31

    Article  CAS  PubMed  Google Scholar 

  4. Kumar D, Verma M (2009) Methods in cancer epigenetics and epidemiology. Methods Mol Biol 471:273–288

    Article  CAS  PubMed  Google Scholar 

  5. Verma M, Maruvada P, Srivastava S (2004) Epigenetics and cancer. Crit Rev Clin Lab Sci 41:585–607

    Article  CAS  PubMed  Google Scholar 

  6. Verma M, Dunn BK, Ross S, Jain P, Wang W, Hayes R et al (2003) Early detection and risk assessment: proceedings and recommendations from the workshop on epigenetics in cancer prevention. Ann N Y Acad Sci 983:298–319

    Article  PubMed  Google Scholar 

  7. Verma M (2003) Viral genes and methylation. Ann N Y Acad Sci 983:170–180

    Article  CAS  PubMed  Google Scholar 

  8. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer 11:726–734

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Han H, Wolff EM, Liang G (2012) Epigenetic alterations in bladder cancer and their potential clinical implications. Adv Urol 2012:546917

    Article  PubMed Central  PubMed  Google Scholar 

  10. Peltomaki P (2012) Mutations and epimutations in the origin of cancer. Exp Cell Res 318:299–310

    Article  PubMed  CAS  Google Scholar 

  11. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG et al (2011) Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med 3:75ra25

    Article  PubMed Central  PubMed  Google Scholar 

  12. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Melichar B, Kroupis C (2012) Cancer epigenomics: moving slowly, but at a steady pace from laboratory bench to clinical practice. Clin Chem Lab Med 50:1699–1701

    CAS  PubMed  Google Scholar 

  14. Chen YL, Ko CJ, Lin PY, Chuang WL, Hsu CC, Chu PY et al (2012) Clustered DNA methylation changes in polycomb target genes in early-stage liver cancer. Biochem Biophys Res Commun 425:290–296

    Article  CAS  PubMed  Google Scholar 

  15. Yi JM, Dhir M, Van Neste L, Downing SR, Jeschke J, Glockner SC et al (2011) Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res 17:1535–1545

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Jeschke J, Van Neste L, Glockner SC, Dhir M, Calmon MF, Deregowski V et al (2012) Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics 7:701–709

    Article  CAS  PubMed  Google Scholar 

  17. Heyn H, Li N, Ferreira HJ, Moran S, Pisano DG, Gomez A et al (2012) Distinct DNA methylomes of newborns and centenarians. Proc Natl Acad Sci U S A 109:10522–10527

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70

    Article  CAS  Google Scholar 

  19. Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C et al (2012) Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov 2:1004–1023

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Wu JH, Liang XA, Wu YM, Li FS, Dai YM (2013) Identification of DNA methylation of SOX9 in cervical cancer using methylated-CpG island recovery assay. Oncol Rep 29:125–132

    PubMed  Google Scholar 

  21. Zhou J, Lv R, Song X, Li D, Hu X, Ying B et al (2012) Association between two genetic variants in miRNA and primary liver cancer risk in the Chinese population. DNA Cell Biol 31:524–530

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Shin CM, Kim N, Jung Y, Park JH, Kang GH, Park WY et al (2011) Genome-wide DNA methylation profiles in noncancerous gastric mucosae with regard to Helicobacter pylori infection and the presence of gastric cancer. Helicobacter 16:179–188

    Article  CAS  PubMed  Google Scholar 

  23. Ricketts CJ, Morris MR, Gentle D, Brown M, Wake N, Woodward ER et al (2012) Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics 7:278–290

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Song JS, Kim YS, Kim DK, Park SI, Jang SJ (2012) Global histone modification pattern associated with recurrence and disease-free survival in non-small cell lung cancer patients. Pathol Int 62:182–190

    Article  PubMed  Google Scholar 

  25. Anglim PP, Alonzo TA, Laird-Offringa IA (2008) DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer 7:81

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  26. Kelloff GJ, Sigman CC (2012) Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 11:201–214

    Article  CAS  PubMed  Google Scholar 

  27. Srinivas PR, Verma M, Zhao Y, Srivastava S (2002) Proteomics for cancer biomarker discovery. Clin Chem 48:1160–1169

    CAS  PubMed  Google Scholar 

  28. Verma M (2012) Epigenetic biomarkers in cancer epidemiology. Methods Mol Biol 863:467–480

    Article  CAS  PubMed  Google Scholar 

  29. Banerjee HN, Verma M (2006) Use of nanotechnology for the development of novel cancer biomarkers. Expert Rev Mol Diagn 6:679–683

    Article  CAS  PubMed  Google Scholar 

  30. Verma M, Manne U (2006) Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. Crit Rev Oncol Hematol 60:9–18

    Article  PubMed  Google Scholar 

  31. Verma M, Seminara D, Arena FJ, John C, Iwamoto K, Hartmuller V (2006) Genetic and epigenetic biomarkers in cancer: improving diagnosis, risk assessment, and disease stratification. Mol Diagn Ther 10:1–15

    Article  CAS  PubMed  Google Scholar 

  32. Verma M (2004) Biomarkers for risk assessment in molecular epidemiology of cancer. Technol Cancer Res Treat 3:505–514

    Article  CAS  PubMed  Google Scholar 

  33. Wagner PD, Verma M, Srivastava S (2004) Challenges for biomarkers in cancer detection. Ann N Y Acad Sci 1022:9–16

    Article  CAS  PubMed  Google Scholar 

  34. Verma M, Srivastava S (2003) New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res 163:72–84, discussion 264–6

    Article  CAS  PubMed  Google Scholar 

  35. Negm RS, Verma M, Srivastava S (2002) The promise of biomarkers in cancer screening and detection. Trends Mol Med 8:288–293

    Article  CAS  PubMed  Google Scholar 

  36. Srivastava S, Verma M, Henson DE (2001) Biomarkers for early detection of colon cancer. Clin Cancer Res 7:1118–1126

    CAS  PubMed  Google Scholar 

  37. Verma M, Khoury MJ, Ioannidis JP (2013) Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling. Cancer Epidemiol Biomarkers Prev 22:189–200

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Gerstung M, Eriksson N, Lin J, Vogelstein B, Beerenwinkel N (2011) The temporal order of genetic and pathway alterations in tumorigenesis. PLoS One 6:e27136

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Ni Y, Xie X, Bu H, Zhang Z, Wei B, Yin L et al (2013) Concurrent primary angiosarcoma and invasive ductal carcinoma in the same breast. J Clin Pathol 66:263–264

    Article  PubMed  Google Scholar 

  41. Blaichman J, Marcus JC, Alsaadi T, El-Khoury M, Meterissian S, Mesurolle B (2012) Sonographic appearance of invasive ductal carcinoma of the breast according to histologic grade. AJR Am J Roentgenol 199:W402–W408

    Article  PubMed  Google Scholar 

  42. Henrique R, Luis AS, Jeronimo C (2012) The epigenetics of renal cell tumors: from biology to biomarkers. Front Genet 3:94

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westra WH et al (2004) Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 64:5511–5517

    Article  CAS  PubMed  Google Scholar 

  44. Brait M, Begum S, Carvalho AL, Dasgupta S, Vettore AL, Czerniak B et al (2008) Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev 17:2786–2794

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W et al (2006) Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 98:996–1004

    Article  CAS  PubMed  Google Scholar 

  46. Peters I, Rehmet K, Wilke N, Kuczyk MA, Hennenlotter J, Eilers T et al (2007) RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer 6:49

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  47. Costa VL, Henrique R, Ribeiro FR, Pinto M, Oliveira J, Lobo F et al (2007) Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer 7:133

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  48. Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T et al (2009) MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 13:3918–3928

    Article  PubMed Central  PubMed  Google Scholar 

  49. Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DJ, Cheng JC, Toma MI et al (2005) Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 41:2769–2778

    Article  CAS  PubMed  Google Scholar 

  50. Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373:1119–1132

    Article  CAS  PubMed  Google Scholar 

  51. Ishihara K, Sasaki D, Tsuruda K, Inokuchi N, Nagai K, Hasegawa H et al (2012) Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia. Cancer Epidemiol 36:560–565

    Article  CAS  PubMed  Google Scholar 

  52. Moussay E, Wang K, Cho JH, van Moer K, Pierson S, Paggetti J et al (2011) MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 108:6573–6578

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Kraguljac Kurtovic N, Krajnovic M, Bogdanovic A, Suvajdzic N, Jovanovic J, Dimitrijevic B et al (2012) Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells. Med Oncol 29:3547–3556

    Article  CAS  PubMed  Google Scholar 

  54. Ammerpohl O, Haake A, Pellissery S, Giefing M, Richter J, Balint B et al (2012) Array-based DNA methylation analysis in classical Hodgkin lymphoma reveals new insights into the mechanisms underlying silencing of B cell-specific genes. Leukemia 26:185–188

    Article  CAS  PubMed  Google Scholar 

  55. Zainuddin N, Kanduri M, Berglund M, Lindell M, Amini RM, Roos G et al (2011) Quantitative evaluation of p16(INK4a) promoter methylation using pyrosequencing in de novo diffuse large B-cell lymphoma. Leuk Res 35:438–443

    Article  CAS  PubMed  Google Scholar 

  56. Alelu-Paz R, Ashour N, Gonzalez-Corpas A, Ropero S (2012) DNA methylation, histone modifications, and signal transduction pathways: a close relationship in malignant gliomas pathophysiology. J Signal Transduct 2012:956958

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  57. Alaminos M, Davalos V, Ropero S, Setien F, Paz MF, Herranz M et al (2005) EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res 65:2565–2571

    Article  CAS  PubMed  Google Scholar 

  58. Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 81:77–82

    Article  CAS  PubMed  Google Scholar 

  59. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G et al (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391–400

    Article  CAS  PubMed  Google Scholar 

  60. Zhang Z, Tang H, Wang Z, Zhang B, Liu W, Lu H et al (2011) MiR-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma. Mol Cancer 10:124

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Di Vinci A, Casciano I, Marasco E, Banelli B, Ravetti GL, Borzi L et al (2012) Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome. J Cancer Res Clin Oncol 138:35–47

    Article  PubMed  CAS  Google Scholar 

  62. Yoo KH, Hennighausen L (2012) EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci 8:59–65

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Buhmeida A, Merdad A, Al-Maghrabi J, Al-Thobaiti F, Ata M, Bugis A et al (2011) RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency. Anticancer Res 31:2975–2981

    CAS  PubMed  Google Scholar 

  64. Wu X, Somlo G, Yu Y, Palomares MR, Li AX, Zhou W et al (2012) De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med 10:42

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  65. Clarke MA, Wentzensen N, Mirabello L, Ghosh A, Wacholder S, Harari A et al (2012) Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol Biomarkers Prev 21:2125–2137

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. Das Ghosh D, Bhattacharjee B, Sen S, Premi L, Mukhopadhyay I, Chowdhury RR et al (2012) Some novel insights on HPV16 related cervical cancer pathogenesis based on analyses of LCR methylation, viral load, E7 and E2/E4 expressions. PLoS One 7:e44678

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  67. Kang WS, Cho SB, Park JS, Lee MY, Myung SC, Kim WY et al (2013) Clinico-epigenetic combination including quantitative methylation value of DKK3 augments survival prediction of the patient with cervical cancer. J Cancer Res Clin Oncol 139:97–106

    Article  CAS  PubMed  Google Scholar 

  68. Abudukadeer A, Bakry R, Goebel G, Mutz-Dehbalaie I, Widschwendter A, Bonn GK et al (2012) Clinical relevance of CDH1 and CDH13 DNA-methylation in serum of cervical cancer patients. Int J Mol Sci 13:8353–8363

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Huang Y, Song H, Hu H, Cui L, You C, Huang L (2012) Trichosanthin inhibits DNA methyltransferase and restores methylation-silenced gene expression in human cervical cancer cells. Mol Med Rep 6:872–878

    CAS  PubMed  Google Scholar 

  70. Jha AK, Nikbakht M, Jain V, Capalash N, Kaur J (2012) p16(INK4a) and p15(INK4b) gene promoter methylation in cervical cancer patients. Oncol Lett 3:1331–1335

    PubMed Central  CAS  PubMed  Google Scholar 

  71. Lof-Ohlin ZM, Levanat S, Sabol M, Sorbe B, Nilsson TK (2011) Promoter methylation in the PTCH gene in cervical epithelial cancer and ovarian cancer tissue as studied by eight novel Pyrosequencing(R) assays. Int J Oncol 38:685–692

    PubMed  Google Scholar 

  72. Jeong DH, Youm MY, Kim YN, Lee KB, Sung MS, Yoon HK et al (2006) Promoter methylation of p16, DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics. Int J Gynecol Cancer 16:1234–1240

    Article  CAS  PubMed  Google Scholar 

  73. Chung MT, Sytwu HK, Yan MD, Shih YL, Chang CC, Yu MH et al (2009) Promoter methylation of SFRPs gene family in cervical cancer. Gynecol Oncol 112:301–306

    Article  CAS  PubMed  Google Scholar 

  74. Jung S, Yi L, Kim J, Jeong D, Oh T, Kim CH et al (2011) The role of vimentin as a methylation biomarker for early diagnosis of cervical cancer. Mol Cells 31:405–411

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Han SW, Lee HJ, Bae JM, Cho NY, Lee KH, Kim TY et al (2013) Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. Int J Cancer 132:2209–2216

    Article  CAS  PubMed  Google Scholar 

  76. Dallol A, Al-Maghrabi J, Buhmeida A, Gari MA, Chaudhary AG, Schulten HJ et al (2012) Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer. Cancer Epidemiol Biomarkers Prev 21:2069–2075

    Article  CAS  PubMed  Google Scholar 

  77. Fang WJ, Zheng Y, Wu LM, Ke QH, Shen H, Yuan Y et al (2012) Genome-wide analysis of aberrant DNA methylation for identification of potential biomarkers in colorectal cancer patients. Asian Pac J Cancer Prev 13:1917–1921

    Article  PubMed  Google Scholar 

  78. Khamas A, Ishikawa T, Mogushi K, Iida S, Ishiguro M, Tanaka H et al (2012) Genome-wide screening for methylation-silenced genes in colorectal cancer. Int J Oncol 41:490–496

    CAS  PubMed  Google Scholar 

  79. Coppede F (2011) Epigenetic biomarkers of colorectal cancer: focus on DNA methylation. Cancer Lett 342(2):238–247

    Article  PubMed  CAS  Google Scholar 

  80. Hibi K, Mizukami H, Saito M, Kigawa G, Nemoto H, Sanada Y (2012) FBN2 methylation is detected in the serum of colorectal cancer patients with hepatic metastasis. Anticancer Res 32:4371–4374

    CAS  PubMed  Google Scholar 

  81. Nilsson TK, Lof-Ohlin ZM, Sun XF (2013) DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients. Int J Oncol 42:127–133

    PubMed Central  CAS  PubMed  Google Scholar 

  82. Moya P, Esteban S, Fernandez-Suarez A, Maestro M, Morente M, Sanchez-Carbayo M (2012) KiSS-1 methylation and protein expression patterns contribute to diagnostic and prognostic assessments in tissue specimens for colorectal cancer. Tumour Biol 34:471–479

    Article  PubMed  CAS  Google Scholar 

  83. Ogino S, Nishihara R, Lochhead P, Imamura Y, Kuchiba A, Morikawa T et al (2013) Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst 105:130–140

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  84. Li BQ, Yu H, Wang Z, Ding GH, Liu L (2013) MicroRNA mediated network and DNA methylation in colorectal cancer. Protein Pept Lett 20:352–363

    CAS  PubMed  Google Scholar 

  85. Tamagawa H, Oshima T, Shiozawa M, Morinaga S, Nakamura Y, Yoshihara M et al (2012) The global histone modification pattern correlates with overall survival in metachronous liver metastasis of colorectal cancer. Oncol Rep 27:637–642

    CAS  PubMed  Google Scholar 

  86. Nakazawa T, Kondo T, Ma D, Niu D, Mochizuki K, Kawasaki T et al (2012) Global histone modification of histone H3 in colorectal cancer and its precursor lesions. Hum Pathol 43:834–842

    Article  CAS  PubMed  Google Scholar 

  87. Banno K, Kisu I, Yanokura M, Masuda K, Kobayashi Y, Ueki A et al (2012) Endometrial cancer and hypermethylation: regulation of DNA and MicroRNA by epigenetics. Biochem Res Int 2012:738274

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  88. Banno K, Kisu I, Yanokura M, Masuda K, Ueki A, Kobayashi Y et al (2012) Epigenetics and genetics in endometrial cancer: new carcinogenic mechanisms and relationship with clinical practice. Epigenomics 4:147–162

    Article  CAS  PubMed  Google Scholar 

  89. Cohn DE, Fabbri M, Valeri N, Alder H, Ivanov I, Liu CG et al (2010) Comprehensive miRNA profiling of surgically staged endometrial cancer. Am J Obstet Gynecol 202:656 e1–656 e8

    Article  PubMed  CAS  Google Scholar 

  90. Tao MH, Freudenheim JL (2010) DNA methylation in endometrial cancer. Epigenetics 5:491–498

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  91. Varier RA, Vermeulen M (2012) Differential epigenetic regulation of GATA4 in gastric adenocarcinomas. Epigenomics 4:367

    Article  CAS  PubMed  Google Scholar 

  92. Jazirehi AR, Arle D, Wenn PB (2012) Role of epigenetic modifications of SOX 9 in gastric carcinoma. Epigenomics 4:253

    Article  CAS  Google Scholar 

  93. Park JH, Park J, Choi JK, Lyu J, Bae MG, Lee YG et al (2011) Identification of DNA methylation changes associated with human gastric cancer. BMC Med Genomics 4:82

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  94. Jung Y, Park J, Bang YJ, Kim TY (2008) Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers. Lab Invest 88:153–160

    Article  CAS  PubMed  Google Scholar 

  95. Ebert MP, Mooney SH, Tonnes-Priddy L, Lograsso J, Hoffmann J, Chen J et al (2005) Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. Neoplasia 7:771–778

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  96. Kim JG, Takeshima H, Niwa T, Rehnberg E, Shigematsu Y, Yoda Y et al (2013) Comprehensive DNA methylation and extensive mutation analyses reveal an association between the CpG island methylator phenotype and oncogenic mutations in gastric cancers. Cancer Lett 330:33–40

    Article  CAS  PubMed  Google Scholar 

  97. Nanjo S, Asada K, Yamashita S, Nakajima T, Nakazawa K, Maekita T et al (2012) Identification of gastric cancer risk markers that are informative in individuals with past H. pylori infection. Gastric Cancer 15:382–388

    Article  CAS  PubMed  Google Scholar 

  98. Ushijima T, Hattori N (2012) Molecular pathways: involvement of helicobacter pylori-triggered inflammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers. Clin Cancer Res 18:923–929

    Article  CAS  PubMed  Google Scholar 

  99. Zabaleta J (2012) MicroRNA: a bridge from H. pylori infection to gastritis and gastric cancer development. Front Genet 3:294

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  100. Huang FY, Chan AO, Rashid A, Wong DK, Cho CH, Yuen MF (2012) Helicobacter pylori induces promoter methylation of E-cadherin via interleukin-1beta activation of nitric oxide production in gastric cancer cells. Cancer 118:4969–4980

    Article  CAS  PubMed  Google Scholar 

  101. Ziogas D, Roukos D (2009) Epigenetics in gastric cancer: challenges for clinical implications. Ann Surg Oncol 16:2077–2078

    Article  CAS  PubMed  Google Scholar 

  102. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ (2008) The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 15:1968–1976

    Article  PubMed  Google Scholar 

  103. Zouridis H, Deng N, Ivanova T, Zhu Y, Wong B, Huang D et al (2012) Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med 4:156ra40

    Article  CAS  Google Scholar 

  104. Chang X, Li Z, Ma J, Deng P, Zhang S, Zhi Y et al (2013) DNA methylation of NDRG2 in gastric cancer and its clinical significance. Dig Dis Sci 58:715–723

    Article  CAS  PubMed  Google Scholar 

  105. Takamaru H, Yamamoto E, Suzuki H, Nojima M, Maruyama R, Yamano HO et al (2012) Aberrant methylation of RASGRF1 is associated with an epigenetic field defect and increased risk of gastric cancer. Cancer Prev Res (Phila) 5:1203–1212

    Article  CAS  Google Scholar 

  106. Yu QM, Wang XB, Luo J, Wang S, Fang XH, Yu JL et al (2012) CDH1 methylation in preoperative peritoneal washes is an independent prognostic factor for gastric cancer. J Surg Oncol 106:765–771

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  107. Alves MK, Ferrasi AC, Lima VP, Ferreira MV, de Moura Campos Pardini MI, Rabenhorst SH (2011) Inactivation of COX-2, HMLH1 and CDKN2A gene by promoter methylation in gastric cancer: relationship with histological subtype, tumor location and helicobacter pylori genotype. Pathobiology 78:266–276

    Article  CAS  PubMed  Google Scholar 

  108. Ando T, Yoshida T, Enomoto S, Asada K, Tatematsu M, Ichinose M et al (2009) DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer 124:2367–2374

    Article  CAS  PubMed  Google Scholar 

  109. Shirahata A, Sakuraba K, Kitamura Y, Yokomizo K, Gotou T, Saitou M et al (2012) Detection of vimentin methylation in the serum of patients with gastric cancer. Anticancer Res 32:791–794

    CAS  PubMed  Google Scholar 

  110. Demokan S, Dalay N (2011) Role of DNA methylation in head and neck cancer. Clin Epigenetics 2:123–150

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  111. Teh MT, Gemenetzidis E, Patel D, Tariq R, Nadir A, Bahta AW et al (2012) FOXM1 induces a global methylation signature that mimics the cancer epigenome in head and neck squamous cell carcinoma. PLoS One 7:e34329

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  112. Demokan S, Chuang A, Suoglu Y, Ulusan M, Yalniz Z, Califano JA et al (2012) Promoter methylation and loss of p16(INK4a) gene expression in head and neck cancer. Head Neck 34:1470–1475

    Article  PubMed  Google Scholar 

  113. Yalniz Z, Demokan S, Suoglu Y, Ulusan M, Dalay N (2011) Simultaneous methylation profiling of tumor suppressor genes in head and neck cancer. DNA Cell Biol 30:17–24

    Article  CAS  PubMed  Google Scholar 

  114. Righini CA, de Fraipont F, Timsit JF, Faure C, Brambilla E, Reyt E et al (2007) Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res 13:1179–1185

    Article  CAS  PubMed  Google Scholar 

  115. Calmon MF, Colombo J, Carvalho F, Souza FP, Filho JF, Fukuyama EE et al (2007) Methylation profile of genes CDKN2A (p14 and p16), DAPK1, CDH1, and ADAM23 in head and neck cancer. Cancer Genet Cytogenet 173:31–37

    Article  CAS  PubMed  Google Scholar 

  116. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT (2002) Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21:4231–4236

    Article  CAS  PubMed  Google Scholar 

  117. Demokan S, Suoglu Y, Demir D, Gozeler M, Dalay N (2006) Microsatellite instability and methylation of the DNA mismatch repair genes in head and neck cancer. Ann Oncol 17:995–999

    Article  CAS  PubMed  Google Scholar 

  118. Biron VL, Dort JC (2008) Epigenetic perspective into head and neck cancer through in silico gene expression profiling of histone lysine methyltransferases. J Otolaryngol Head Neck Surg 37:366–372

    PubMed  Google Scholar 

  119. Peters I, Eggers H, Atschekzei F, Hennenlotter J, Waalkes S, Trankenschuh W et al (2012) GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression. BJU Int 110:E144–E152

    Article  CAS  PubMed  Google Scholar 

  120. Eggers H, Steffens S, Grosshennig A, Becker JU, Hennenlotter J, Stenzl A et al (2012) Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma. Int J Oncol 40:1650–1658

    CAS  PubMed  Google Scholar 

  121. Atschekzei F, Hennenlotter J, Janisch S, Grosshennig A, Trankenschuh W, Waalkes S et al (2012) SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence. Epigenetics 7:447–457

    Article  CAS  PubMed  Google Scholar 

  122. Liao LM, Brennan P, van Bemmel DM, Zaridze D, Matveev V, Janout V et al (2011) LINE-1 methylation levels in leukocyte DNA and risk of renal cell cancer. PLoS One 6:e27361

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  123. Fritzsche FR, Weichert W, Roske A, Gekeler V, Beckers T, Stephan C et al (2008) Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8:381

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  124. Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P et al (2010) Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 29:5724–5728

    Article  CAS  PubMed  Google Scholar 

  125. Varier RA, Vermeulen M (2012) Epigenetics and the prognosis of hepatocellular carcinoma. Epigenomics 4:368

    Article  PubMed  CAS  Google Scholar 

  126. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T et al (2004) Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40:667–676

    Article  CAS  PubMed  Google Scholar 

  127. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA et al (2007) Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 117:2713–2722

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  128. Lambert MP, Paliwal A, Vaissiere T, Chemin I, Zoulim F, Tommasino M et al (2011) Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol 54:705–715

    Article  CAS  PubMed  Google Scholar 

  129. He C, Xu J, Zhang J, Xie D, Ye H, Xiao Z et al (2012) High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum Pathol 43:1425–1435

    Article  CAS  PubMed  Google Scholar 

  130. Gao W, Xu J, Shu YQ (2011) miRNA expression and its clinical implications for the prevention and diagnosis of non-small-cell lung cancer. Expert Rev Respir Med 5:699–709

    Article  CAS  PubMed  Google Scholar 

  131. Lin PY, Yang PC (2011) Circulating miRNA signature for early diagnosis of lung cancer. EMBO Mol Med 3:436–437

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  132. Keller A, Leidinger P, Gislefoss R, Haugen A, Langseth H, Staehler P et al (2011) Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol 8:506–516

    Article  CAS  PubMed  Google Scholar 

  133. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H et al (2010) Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 67:170–176

    Article  PubMed Central  PubMed  Google Scholar 

  134. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E et al (1998) Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 95:11891–11896

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  135. Anglim PP, Galler JS, Koss MN, Hagen JA, Turla S, Campan M et al (2008) Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol Cancer 7:62

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  136. Leng S, Do K, Yingling CM, Picchi MA, Wolf HJ, Kennedy TC et al (2012) Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clin Cancer Res 18:3387–3395

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  137. Yu GP, Ji Y, Chen GQ, Huang B, Shen K, Wu S et al (2012) Application of RUNX3 gene promoter methylation in the diagnosis of non-small cell lung cancer. Oncol Lett 3:159–162

    PubMed Central  CAS  PubMed  Google Scholar 

  138. Dietrich D, Kneip C, Raji O, Liloglou T, Seegebarth A, Schlegel T et al (2012) Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int J Oncol 40:825–832

    CAS  PubMed  Google Scholar 

  139. Schmidt B, Liebenberg V, Dietrich D, Schlegel T, Kneip C, Seegebarth A et al (2010) SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 10:600

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  140. Begum S, Brait M, Dasgupta S, Ostrow KL, Zahurak M, Carvalho AL et al (2011) An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res 17:4494–4503

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  141. Gloss BS, Samimi G (2012) Epigenetic biomarkers in epithelial ovarian cancer. Cancer Lett 342(2):257–263

    Article  PubMed  CAS  Google Scholar 

  142. Kashuba V, Dmitriev AA, Krasnov GS, Pavlova T, Ignatjev I, Gordiyuk VV et al (2012) NotI microarrays: novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer. Int J Mol Sci 13:13352–13377

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  143. Kisiel JB, Yab TC, Taylor WR, Chari ST, Petersen GM, Mahoney DW et al (2012) Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates. Cancer 118:2623–2631

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  144. Kumari A, Srinivasan R, Vasishta RK, Wig JD (2009) Positive regulation of human telomerase reverse transcriptase gene expression and telomerase activity by DNA methylation in pancreatic cancer. Ann Surg Oncol 16:1051–1059

    Article  PubMed  Google Scholar 

  145. Li M, Zhao ZW (2012) Clinical implications of mismatched repair gene promoter methylation in pancreatic cancer. Med Oncol 29:970–976

    Article  CAS  PubMed  Google Scholar 

  146. Liggett T, Melnikov A, Yi QL, Replogle C, Brand R, Kaul K et al (2010) Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer 116:1674–1680

    Article  CAS  PubMed  Google Scholar 

  147. Matsubayashi H, Sato N, Fukushima N, Yeo CJ, Walter KM, Brune K et al (2003) Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res 9:1446–1452

    CAS  PubMed  Google Scholar 

  148. Omura N, Goggins M (2009) Epigenetics and epigenetic alterations in pancreatic cancer. Int J Clin Exp Pathol 2:310–326

    PubMed Central  CAS  PubMed  Google Scholar 

  149. Grzenda A, Ordog T, Urrutia R (2011) Polycomb and the emerging epigenetics of pancreatic cancer. J Gastrointest Cancer 42:100–111

    Article  PubMed Central  PubMed  Google Scholar 

  150. Cooper CS, Foster CS (2009) Concepts of epigenetics in prostate cancer development. Br J Cancer 100:240–245

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  151. Dobosy JR, Roberts JL, Fu VX, Jarrard DF (2007) The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 177:822–831

    Article  CAS  PubMed  Google Scholar 

  152. Sullivan L, Murphy TM, Barrett C, Loftus B, Thornhill J, Lawler M et al (2012) IGFBP7 promoter methylation and gene expression analysis in prostate cancer. J Urol 188:1354–1360

    Article  CAS  PubMed  Google Scholar 

  153. Olkhov-Mitsel E, Van der Kwast T, Kron KJ, Ozcelik H, Briollais L, Massey C et al (2012) Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics 7:1037–1045

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  154. Shaikhibrahim Z, Lindstrot A, Ochsenfahrt J, Fuchs K, Wernert N (2013) Epigenetics-related genes in prostate cancer: expression profile in prostate cancer tissues, androgen-sensitive and -insensitive cell lines. Int J Mol Med 31:21–25

    PubMed Central  CAS  PubMed  Google Scholar 

  155. Paone A, Galli R, Fabbri M (2011) MicroRNAs as new characters in the plot between epigenetics and prostate cancer. Front Genet 2:62

    Article  PubMed Central  PubMed  Google Scholar 

  156. Alshalalfa M (2012) MicroRNA response elements-mediated miRNA-miRNA interactions in prostate cancer. Adv Bioinformatics 2012:839837

    PubMed Central  PubMed  Google Scholar 

  157. Majid S, Dar AA, Saini S, Shahryari V, Arora S, Zaman MS et al (2013) MiRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res 19:73–84

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  158. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J (2011) Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77:1265 e9–1265 e16

    Article  PubMed  Google Scholar 

  159. Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, Klee GG et al (2012) Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 18:2882–2895

    Article  CAS  PubMed  Google Scholar 

  160. Wu W, Zhang J, Yang H, Shao Y, Yu B (2011) Examination of AKAP12 promoter methylation in skin cancer using methylation-sensitive high-resolution melting analysis. Clin Exp Dermatol 36:381–385

    Article  CAS  PubMed  Google Scholar 

  161. Chen YC, Guo YL, Su HJ, Hsueh YM, Smith TJ, Ryan LM et al (2003) Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med 45:241–248

    Article  CAS  PubMed  Google Scholar 

  162. Yu RC, Hsu KH, Chen CJ, Froines JR (2000) Arsenic methylation capacity and skin cancer. Cancer Epidemiol Biomarkers Prev 9:1259–1262

    CAS  PubMed  Google Scholar 

  163. Burgess DJ (2012) Epigenetics: melanoma insights written in the DNA. Nat Rev Cancer 12:738–739

    Article  CAS  PubMed  Google Scholar 

  164. Nguyen T, Kuo C, Nicholl MB, Sim MS, Turner RR, Morton DL et al (2011) Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 6:388–394

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  165. Xu X, Jin H, Liu Y, Liu L, Wu Q, Guo Y et al (2012) The expression patterns and correlations of claudin-6, methy-CpG binding protein 2, DNA methyltransferase 1, histone deacetylase 1, acetyl-histone H3 and acetyl-histone H4 and their clinicopathological significance in breast invasive ductal carcinomas. Diagn Pathol 7:33

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  166. Bosch LJ, Mongera S, Terhaar Sive Droste JS, Oort FA, van Turenhout ST, Penning MT et al (2012) Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection. Cell Oncol (Dordr) 35:309–315

    Article  CAS  Google Scholar 

  167. Elliott GO, Johnson IT, Scarll J, Dainty J, Williams EA, Garg D et al (2013) Quantitative profiling of CpG island methylation in human stool for colorectal cancer detection. Int J Colorectal Dis 28:35–42

    Article  PubMed  Google Scholar 

  168. Patchsung M, Boonla C, Amnattrakul P, Dissayabutra T, Mutirangura A, Tosukhowong P (2012) Long interspersed nuclear element-1 hypomethylation and oxidative stress: correlation and bladder cancer diagnostic potential. PLoS One 7:e37009

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  169. Zhu W, Qin W, Hewett JE, Sauter ER (2010) Quantitative evaluation of DNA hypermethylation in malignant and benign breast tissue and fluids. Int J Cancer 126:474–482

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  170. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P (2004) Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 10:6189–6193

    Article  CAS  PubMed  Google Scholar 

  171. Nelson HH, Marsit CJ, Christensen BC, Houseman EA, Kontic M, Wiemels JL et al (2012) Key epigenetic changes associated with lung cancer development: results from dense methylation array profiling. Epigenetics 7:559–566

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  172. Langevin SM, Koestler DC, Christensen BC, Butler RA, Wiencke JK, Nelson HH et al (2012) Peripheral blood DNA methylation profiles are indicative of head and neck squamous cell carcinoma: an epigenome-wide association study. Epigenetics 7:291–299

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  173. Marsit CJ, Houseman EA, Christensen BC, Gagne L, Wrensch MR, Nelson HH et al (2010) Identification of methylated genes associated with aggressive bladder cancer. PLoS One 5:e12334

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  174. Yan C, Kim YW, Ha YS, Kim IY, Kim YJ, Yun SJ et al (2012) RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer. J Surg Oncol 105:425–430

    Article  CAS  PubMed  Google Scholar 

  175. Ben Gacem R, Hachana M, Ziadi S, Amara K, Ksia F, Mokni M et al (2012) Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients. Cancer Epidemiol 36:190–197

    Article  CAS  PubMed  Google Scholar 

  176. Poage GM, Butler RA, Houseman EA, McClean MD, Nelson HH, Christensen BC et al (2012) Identification of an epigenetic profile classifier that is associated with survival in head and neck cancer. Cancer Res 72:2728–2737

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  177. Marsit CJ, McClean MD, Furniss CS, Kelsey KT (2006) Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. Int J Cancer 119:1761–1766

    Article  CAS  PubMed  Google Scholar 

  178. Ling ZQ, Zhao Q, Zhou SL, Mao WM (2012) MSH2 promoter hypermethylation in circulating tumor DNA is a valuable predictor of disease-free survival for patients with esophageal squamous cell carcinoma. Eur J Surg Oncol 38:326–332

    Article  CAS  PubMed  Google Scholar 

  179. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y et al (2010) Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28:1721–1726

    Article  PubMed  Google Scholar 

  180. Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW et al (2010) MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 16:430–441

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  181. Teo MT, Landi D, Taylor CF, Elliott F, Vaslin L, Cox DG et al (2012) The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. Carcinogenesis 33:581–586

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  182. Boumber Y, Issa JP (2011) Epigenetics in cancer: what’s the future? Oncology (Williston Park) 25:220–226

    Google Scholar 

  183. Yan P, Frankhouser D, Murphy M, Tam HH, Rodriguez B, Curfman J et al (2012) Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood 120:2466–2474

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  184. Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang E et al (2012) Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat 132:1063–1072

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  185. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B et al (2011) Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 1:598–607

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  186. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M et al (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93:1054–1061

    Article  CAS  PubMed  Google Scholar 

  187. Khoury MJ, Freedman AN, Gillanders EM, Harvey CE, Kaefer C, Reid BC et al (2012) Frontiers in cancer epidemiology: a challenge to the research community from the epidemiology and genomics research program at the national cancer institute. Cancer Epidemiol Biomarkers Prev 21:999–1001

    Article  PubMed Central  PubMed  Google Scholar 

  188. Verma M (2009) Proteomics and cancer epidemiology. Methods Mol Biol 471:197–215

    Article  CAS  PubMed  Google Scholar 

  189. Verma M, Kumar D (2007) Application of mitochondrial genome information in cancer epidemiology. Clin Chim Acta 383:41–50

    Article  CAS  PubMed  Google Scholar 

  190. Verma M, Naviaux RK, Tanaka M, Kumar D, Franceschi C, Singh KK (2007) Meeting report: mitochondrial DNA and cancer epidemiology. Cancer Res 67:437–439

    Article  CAS  PubMed  Google Scholar 

  191. Verma M (2005) Pancreatic cancer epidemiology. Technol Cancer Res Treat 4:295–301

    Article  CAS  PubMed  Google Scholar 

  192. van Bemmel D, Lenz P, Liao LM, Baris D, Sternberg LR, Warner A et al (2012) Correlation of LINE-1 methylation levels in patient-matched buffy coat, serum, buccal cell, and bladder tumor tissue DNA samples. Cancer Epidemiol Biomarkers Prev 21:1143–1148

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  193. Koestler DC, Marsit CJ, Christensen BC, Accomando W, Langevin SM, Houseman EA et al (2012) Peripheral blood immune cell methylation profiles are associated with nonhematopoietic cancers. Cancer Epidemiol Biomarkers Prev 21:1293–1302

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  194. Sturgeon SR, Balasubramanian R, Schairer C, Muss HB, Ziegler RG, Arcaro KF (2012) Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls. Epigenetics 7:1258–1267

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  195. von Deimling A, Korshunov A, Hartmann C (2011) The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21:74–87

    Article  CAS  Google Scholar 

  196. Rather MI, Nagashri MN, Swamy SS, Gopinath KS, Kumar A (2013) Oncogenic microRNA-155 downregulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implications for cancer therapeutics. J Biol Chem 288:608–618

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  197. Koike K, Kasamatsu A, Iyoda M, Saito Y, Kouzu Y, Koike H et al (2013) High prevalence of epigenetic inactivation of the human four and a half LIM domains 1 gene in human oral cancer. Int J Oncol 42:141–150

    CAS  PubMed  Google Scholar 

  198. Shaw RJ, Hobkirk AJ, Nikolaidis G, Woolgar JA, Triantafyllou A, Brown JS et al (2013) Molecular staging of surgical margins in oral squamous cell carcinoma using promoter methylation of p16(INK4A), cytoglobin, E-cadherin, and TMEFF2. Ann Surg Oncol 20(8):2796–2802

    Google Scholar 

  199. Zhou J, Cao J, Lu Z, Liu H, Deng D (2011) A 115-bp MethyLight assay for detection of p16 (CDKN2A) methylation as a diagnostic biomarker in human tissues. BMC Med Genet 12:67

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  200. Sasahira T, Ueda N, Yamamoto K, Bhawal UK, Kurihara M, Kirita T et al (2013) Trks are novel oncogenes involved in the induction of neovascularization, tumor progression, and nodal metastasis in oral squamous cell carcinoma. Clin Exp Metastasis 30:165–176

    Article  CAS  PubMed  Google Scholar 

  201. Kordi-Tamandani DM, Ladies MA, Hashemi M, Moazeni-Roodi AK, Krishna S, Torkamanzehi A (2012) Analysis of p15INK4b and p16INK4a gene methylation in patients with oral squamous cell carcinoma. Biochem Genet 50:448–453

    Article  CAS  PubMed  Google Scholar 

  202. Minor J, Wang X, Zhang F, Song J, Jimeno A, Wang XJ et al (2012) Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas. Oral Oncol 48:73–78

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  203. Gasche JA, Hoffmann J, Boland CR, Goel A (2011) Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells. Int J Cancer 129:1053–1063

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  204. Guerrero-Preston R, Soudry E, Acero J, Orera M, Moreno-Lopez L, Macia-Colon G et al (2011) NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva. Cancer Prev Res (Phila) 4:1061–1072

    Article  CAS  Google Scholar 

  205. Biron VL, Mohamed A, Hendzel MJ, Alan Underhill D, Seikaly H (2012) Epigenetic differences between human papillomavirus-positive and -negative oropharyngeal squamous cell carcinomas. J Otolaryngol Head Neck Surg 41(Suppl 1):S65–S70

    PubMed  Google Scholar 

  206. Cheung HH, Davis AJ, Lee TL, Pang AL, Nagrani S, Rennert OM et al (2011) Methylation of an intronic region regulates miR-199a in testicular tumor malignancy. Oncogene 30:3404–3415

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  207. Lee SH, Appleby V, Jeyapalan JN, Palmer RD, Nicholson JC, Sottile V et al (2011) Variable methylation of the imprinted gene, SNRPN, supports a relationship between intracranial germ cell tumours and neural stem cells. J Neurooncol 101:419–428

    Article  CAS  PubMed  Google Scholar 

  208. Xiao L, Wang Y, Zhou Y, Sun Y, Sun W, Wang L et al (2010) Identification of a novel human cancer/testis gene MAEL that is regulated by DNA methylation. Mol Biol Rep 37:2355–2360

    Article  CAS  PubMed  Google Scholar 

  209. Sugimoto K, Koh E, Sin HS, Maeda Y, Narimoto K, Izumi K et al (2009) Tissue-specific differentially methylated regions of the human VASA gene are potentially associated with maturation arrest phenotype in the testis. J Hum Genet 54:450–456

    Article  CAS  PubMed  Google Scholar 

  210. Marsit CJ, Karagas MR, Andrew A, Liu M, Danaee H, Schned AR et al (2005) Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res 65:7081–7085

    Article  CAS  PubMed  Google Scholar 

  211. Liu BL, Cheng JX, Zhang W, Zhang X, Wang R, Lin H et al (2010) Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro Oncol 12:540–548

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  212. Sebova K, Zmetakova I, Bella V, Kajo K, Stankovicova I, Kajabova V et al (2011) RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Biomark 10:13–26

    CAS  PubMed  Google Scholar 

  213. Kishi T, Tanaka Y, Ueda K (2000) Evidence for hypomethylation in two children with acute lymphoblastic leukemia and leukoencephalopathy. Cancer 89:925–931

    Article  CAS  PubMed  Google Scholar 

  214. Szaumkessel M, Richter J, Giefing M, Jarmuz M, Kiwerska K, Tonnies H et al (2011) Pyrosequencing-based DNA methylation profiling of Fanconi anemia/BRCA pathway genes in laryngeal squamous cell carcinoma. Int J Oncol 39:505–514

    CAS  PubMed  Google Scholar 

  215. Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M, Gazdar AF (2001) Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 7:584–589

    CAS  PubMed  Google Scholar 

  216. Cortese R, Kwan A, Lalonde E, Bryzgunova O, Bondar A, Wu Y et al (2012) Epigenetic markers of prostate cancer in plasma circulating DNA. Hum Mol Genet 21:3619–3631

    Article  CAS  PubMed  Google Scholar 

  217. Tokarz P, Blasiak J (2012) The role of MiRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol 59:467–474

    CAS  PubMed  Google Scholar 

  218. Selth LA, Tilley WD, Butler LM (2012) Circulating microRNAs: macro-utility as markers of prostate cancer? Endocr Relat Cancer 19:R99–R113

    Article  CAS  PubMed  Google Scholar 

  219. Piyathilake CJ, Macaluso M, Alvarez RD, Chen M, Badiga S, Siddiqui NR et al (2011) A higher degree of LINE-1 methylation in peripheral blood mononuclear cells, a one-carbon nutrient related epigenetic alteration, is associated with a lower risk of developing cervical intraepithelial neoplasia. Nutrition 27:513–519

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  220. Sun C, Reimers LL, Burk RD (2011) Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer. Gynecol Oncol 121:59–63

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  221. Apostolidou S, Hadwin R, Burnell M, Jones A, Baff D, Pyndiah N et al (2009) DNA methylation analysis in liquid-based cytology for cervical cancer screening. Int J Cancer 125:2995–3002

    Article  CAS  PubMed  Google Scholar 

  222. Sathyanarayana UG, Maruyama R, Padar A, Suzuki M, Bondaruk J, Sagalowsky A et al (2004) Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res 64:1425–1430

    Article  CAS  PubMed  Google Scholar 

  223. Antill YC, Mitchell G, Johnson SA, Devereux L, Milner A, Di Iulio J et al (2010) Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 19:265–274

    Article  CAS  PubMed  Google Scholar 

  224. Miyake M, Gomes Giacoia E, Aguilar Palacios D, Rosser CJ (2012) Lung cancer risk assessment for smokers: gene promoter methylation signature in sputum. Biomarker Med 6:512

    Google Scholar 

  225. Flores KG, Stidley CA, Mackey AJ, Picchi MA, Stabler SP, Siegfried JM et al (2012) Sex-specific association of sequence variants in CBS and MTRR with risk for promoter hypermethylation in the lung epithelium of smokers. Carcinogenesis 33:1542–1547

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  226. Guzman L, Depix MS, Salinas AM, Roldan R, Aguayo F, Silva A et al (2012) Analysis of aberrant methylation on promoter sequences of tumor suppressor genes and total DNA in sputum samples: a promising tool for early detection of COPD and lung cancer in smokers. Diagn Pathol 7:87

    Article  PubMed Central  PubMed  Google Scholar 

  227. Kunte DP, DelaCruz M, Wali RK, Menon A, Du H, Stypula Y et al (2012) Dysregulation of microRNAs in colonic field carcinogenesis: implications for screening. PLoS One 7:e45591

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  228. Faryna M, Konermann C, Aulmann S, Bermejo JL, Brugger M, Diederichs S et al (2012) Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J 26:4937–4950

    Article  CAS  PubMed  Google Scholar 

  229. Lendvai A, Johannes F, Grimm C, Eijsink JJ, Wardenaar R, Volders HH et al (2012) Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia. Epigenetics 7:1268–1278

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  230. Botla SK, Gholami AM, Malekpour M, Moskalev EA, Fallah M, Jandaghi P et al (2012) Diagnostic values of GHSR DNA methylation pattern in breast cancer. Breast Cancer Res Treat 135:705–713

    Article  CAS  PubMed  Google Scholar 

  231. Sporn JC, Jung B (2012) Differential regulation and predictive potential of MacroH2A1 isoforms in colon cancer. Am J Pathol 180:2516–2526

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  232. Dimitriadis E, Kalogeropoulos T, Velaeti S, Sotiriou S, Vassiliou E, Fasoulis L et al (2013) Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer. Anticancer Res 33:191–197

    CAS  PubMed  Google Scholar 

  233. Kim YK, Kim WJ (2009) Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol 16:17–22

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

I am thankful to Joanne Brodsky of SCG, Inc., for reading the manuscript and providing suggestions.

Author information

Authors and Affiliations

  1. Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute (NCI), National Institutes of Health (NIH), Suite# 4E102. 9609 Medical Center Drive, MSC 9763, Bethesda, MD, 20892-9726, USA

    Mukesh Verma

Authors
  1. Mukesh Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mukesh Verma .

Editor information

Editors and Affiliations

  1. Institute of Biochemistry and Clinical B, Catholic University School of Medicine, Rome, Italy

    Roberto Scatena

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Verma, M. (2015). The Role of Epigenomics in the Study of Cancer Biomarkers and in the Development of Diagnostic Tools. In: Scatena, R. (eds) Advances in Cancer Biomarkers. Advances in Experimental Medicine and Biology, vol 867. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7215-0_5

Download citation

Publish with us

Policies and ethics

Search

Navigation